Chatterjee Satabdi, Chen Hua, Johnson Michael L, Aparasu Rajender R
Department of Clinical Sciences and Administration, College of Pharmacy, University of Houston, Texas Medical Center, Houston, Texas, USA.
Am J Geriatr Pharmacother. 2012 Apr;10(2):83-94. doi: 10.1016/j.amjopharm.2011.10.006. Epub 2012 Feb 10.
Atypical antipsychotic agents are extensively prescribed in the elderly to treat various behavioral and psychiatric disorders. Past literature has documented an increased risk of falls and factures with the use of risperidone and olanzapine compared with nonuse. However, none of the studies assessed the comparative safety profiles of atypical agents with respect to falls and fractures.
The goal of this study was to evaluate the risk of falls and fractures associated with the use of risperidone, olanzapine, and quetiapine in community-dwelling adults aged ≥50 years.
The study involved a propensity score-adjusted approach in new users of risperidone, olanzapine, or quetiapine anytime between July 1, 2000, and June 30, 2008, using data from the IMS LifeLink Health Plan Claims database. Patients were followed up until a hospitalization/emergency department visit for fall/fracture or the end of the study period, whichever occurred earlier. The Cox proportional hazards regression model was used to evaluate the comparative risk of falls/fractures. The covariates in the final model included propensity scores and their interaction terms.
There were 12,145 new users of atypical agents in the study population (5083 risperidone, 4377 olanzapine, and 2685 quetiapine). A total of 417 cases of falls/fractures with at least 1 hospitalization/ emergency department visit after the use of the antipsychotic agents were identified. The number of falls for risperidone, olanzapine, and quetiapine were 179 (3.56%), 123 (2.84%), and 115 (4.34%), respectively. After adjusting for propensity scores, the Cox proportional hazards model showed that there was no statistically significant difference with use of risperidone (hazard ratio = 1.10 [95% CI, 0.86-1.39]) or quetiapine (hazard ratio = 1.12 [95% CI, 0.86-1.46]) compared with olanzapine (reference group) in the risk of falls or fractures.
The study found no significant difference across the individual atypical agents in the risk of falls/fractures in community-dwelling older adults. Future studies are required to evaluate the overall safety profiles of the antipsychotic agents in this population.
非典型抗精神病药物在老年人中被广泛用于治疗各种行为和精神障碍。过去的文献记载,与未使用相比,使用利培酮和奥氮平会增加跌倒和骨折的风险。然而,没有研究评估非典型药物在跌倒和骨折方面的比较安全性。
本研究的目的是评估≥50岁社区居住成年人使用利培酮、奥氮平和喹硫平与跌倒和骨折相关的风险。
该研究采用倾向评分调整方法,使用IMS LifeLink健康计划索赔数据库的数据,纳入2000年7月1日至2008年6月30日期间任何时间开始使用利培酮、奥氮平或喹硫平的新使用者。对患者进行随访,直至因跌倒/骨折住院/急诊就诊或研究期结束,以先发生者为准。采用Cox比例风险回归模型评估跌倒/骨折的比较风险。最终模型中的协变量包括倾向评分及其交互项。
研究人群中有12145名非典型药物新使用者(5083名利培酮使用者、4377名奥氮平使用者和2685名喹硫平使用者)。共识别出417例使用抗精神病药物后至少有1次住院/急诊就诊的跌倒/骨折病例。利培酮、奥氮平和喹硫平的跌倒病例数分别为179例(3.56%)、123例(2.84%)和115例(4.34%)。在调整倾向评分后,Cox比例风险模型显示,与奥氮平(参照组)相比,使用利培酮(风险比=1.10[95%CI,0.86-1.39])或喹硫平(风险比=1.12[95%CI,0.86-1.46])在跌倒或骨折风险方面无统计学显著差异。
该研究发现,在社区居住的老年人中,不同非典型药物在跌倒/骨折风险方面无显著差异。未来需要开展研究来评估该人群中抗精神病药物的整体安全性。